Plasmablastic Lymphoma (PBL)

Categories: Blood diseases, Immune diseases, Oral diseases, Rare diseases

Aliases & Classifications for Plasmablastic Lymphoma

MalaCards integrated aliases for Plasmablastic Lymphoma:

Name: Plasmablastic Lymphoma 53 59 72
Immunoblastic Large-Cell Lymphoma 72
Pbl 59


External Ids:

ICD10 via Orphanet 34 C83.3
UMLS via Orphanet 73 C3472614
Orphanet 59 ORPHA289666
UMLS 72 C0079746 C3472614

Summaries for Plasmablastic Lymphoma

NIH Rare Diseases : 53 Plasmablastic lymphoma is an aggressive form of non-Hodgkin lymphoma. Although the condition most commonly occurs in the oral cavity, it can be diagnosed in many other parts of the body such as the gastrointestinal tract, lymph nodes, and skin. The exact underlying cause of plasmablastic lymphoma is poorly understood; however, it is often associated with suppression of the immune system (i.e. HIV infection, immunosuppressive therapy). There is currently no standard therapy for plasmablastic lymphoma. Treatment usually consists of chemotherapy with or without radiation therapy and hematopoietic stem cell transplantation.

MalaCards based summary : Plasmablastic Lymphoma, also known as immunoblastic large-cell lymphoma, is related to acquired immunodeficiency syndrome and primary effusion lymphoma. An important gene associated with Plasmablastic Lymphoma is MYC (MYC Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Clavulanate and Ciprofloxacin have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are Reduced mammosphere formation and cellular

Wikipedia : 75 Plasmablastic lymphoma is a type of large B-cell lymphoma, recognized in the WHO 2008... more...

Related Diseases for Plasmablastic Lymphoma

Diseases related to Plasmablastic Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 243)
# Related Disease Score Top Affiliating Genes
1 acquired immunodeficiency syndrome 31.4 MYC CD38 BCL6
2 primary effusion lymphoma 31.3 MYC BCL6
3 diffuse large b-cell lymphoma 31.1 PRDM1 MYC BCL6
4 plasmacytoma 31.0 PTPRC MYC CD38
5 suppressor of tumorigenicity 3 30.9 MYC CDKN2A
6 multicentric castleman disease 30.8 BCL6 ABCB1
7 spindle cell sarcoma 30.5 MUC1 DES
8 lymphocytic leukemia 30.5 NOTCH1 MYC CD38
9 burkitt lymphoma 30.4 MYC MS4A1 BCL6
10 richter's syndrome 30.3 NOTCH1 MYC CD38
11 small cell cancer of the lung 30.2 MYC CDKN2A ABCB1
12 mantle cell lymphoma 29.6 PTPRC MYC MTOR CDKN2A BCL6
13 central nervous system lymphoma 29.6 PRDM1 CDKN2A BCL6
14 leukemia, chronic lymphocytic 29.3 NOTCH1 MS4A1 CD38 BCL6 ABCB1
15 cervical cancer 29.2 NOTCH1 MYC MTOR CDKN2A
16 leukemia, acute myeloid 29.2 PTPRC MYC MTOR CD38 ABCB1
17 lymphoma, non-hodgkin, familial 29.1 PTPRC NOTCH1 MYC MS4A1 CD38 BCL6
18 myeloma, multiple 28.9 PTPRC PRDM1 MYC CDKN2A CD38 ABCB1
19 caspase 8 deficiency 11.3
20 lymphoma 11.0
21 b-cell lymphoma 10.9
22 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.7 MYC BCL6
23 lymphoma, hodgkin, classic 10.7
24 primary mediastinal large b-cell lymphoma 10.6 MYC BCL6
25 heart lymphoma 10.6 PTPRC BCL6
26 immune deficiency disease 10.6
27 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.6 PTPRC BCL6
28 testicular lymphoma 10.6 PTPRC BCL6
29 primary cutaneous anaplastic large cell lymphoma 10.6 PTPRC MUC1
30 ovarian lymphoma 10.6 PTPRC MYC
31 malignant peritoneal mesothelioma 10.5 MUC1 CDKN2A
32 peritoneal mesothelioma 10.5 MUC1 CDKN2A
33 human herpesvirus 8 10.5
34 cutaneous leiomyosarcoma 10.5 MUC1 DES
35 bile duct adenoma 10.5 MUC1 CDKN2A
36 spindle cell thymoma 10.5 MUC1 DES
37 epidural neoplasm 10.5 PTPRC BCL6
38 endometrial mucinous adenocarcinoma 10.5 MUC1 CDKN2A
39 primitive neuroectodermal tumor of the cervix uteri 10.5 PTPRC DES
40 syringocystadenoma papilliferum 10.5 MUC1 DES
41 parachordoma 10.5 MUC1 DES
42 megaesophagus 10.5 MYC CDKN2A
43 malignant fibrous histiocytoma of bone 10.5 MYC DES
44 ossifying fibromyxoid tumor 10.5 MUC1 DES
45 biphasic synovial sarcoma 10.5 MUC1 DES
46 sarcomatoid mesothelioma 10.5 MUC1 CDKN2A
47 spindle cell rhabdomyosarcoma 10.5 MUC1 DES
48 kaposi sarcoma 10.5
49 gamma heavy chain disease 10.4 PTPRC CD38
50 syringoma 10.4 MUC1 DES

Graphical network of the top 20 diseases related to Plasmablastic Lymphoma:

Diseases related to Plasmablastic Lymphoma

Symptoms & Phenotypes for Plasmablastic Lymphoma

GenomeRNAi Phenotypes related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 BCL6 DES MTOR MYC NOTCH1 PTPRC

MGI Mouse Phenotypes related to Plasmablastic Lymphoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.21 BCL6 CD38 CDKN2A DES MTOR MYC
2 cardiovascular system MP:0005385 10.18 ABCB1 BCL6 CDKN2A DES MTOR MYC
3 endocrine/exocrine gland MP:0005379 10.18 ABCB1 BCL6 CD38 CDKN2A MTOR MYC
4 hematopoietic system MP:0005397 10.17 ABCB1 BCL6 CD38 CDKN2A MS4A1 MTOR
5 homeostasis/metabolism MP:0005376 10.14 ABCB1 BCL6 CD38 CDKN2A DES MTOR
6 growth/size/body region MP:0005378 10.11 ABCB1 BCL6 CDKN2A MTOR MYC NOTCH1
7 immune system MP:0005387 10.11 ABCB1 BCL6 CD38 CDKN2A MS4A1 MTOR
8 digestive/alimentary MP:0005381 9.97 ABCB1 CDKN2A MYC NOTCH1 PTPRC VDR
9 mortality/aging MP:0010768 9.96 ABCB1 BCL6 CDKN2A DES MTOR MYC
10 liver/biliary system MP:0005370 9.87 ABCB1 BCL6 CDKN2A MYC NOTCH1 PRDM1
11 muscle MP:0005369 9.76 BCL6 CDKN2A DES MTOR MYC NOTCH1
12 neoplasm MP:0002006 9.35 CDKN2A MYC NOTCH1 PRDM1 PTPRC
13 no phenotypic analysis MP:0003012 9.17 ABCB1 BCL6 CDKN2A MTOR MYC PRDM1

Drugs & Therapeutics for Plasmablastic Lymphoma

Drugs for Plasmablastic Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 408)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
4 Orange Approved Phase 3
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
Etoposide Approved Phase 3 33419-42-0 36462
rituximab Approved Phase 3 174722-31-7 10201696
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
Idarubicin Approved Phase 3 58957-92-9 42890
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
Carmustine Approved, Investigational Phase 3 154-93-8 2578
Melphalan Approved Phase 3 148-82-3 460612 4053
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
Acyclovir Approved Phase 3 59277-89-3 2022
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
Dalteparin Approved Phase 3 9005-49-6
Ofloxacin Approved Phase 3 82419-36-1 4583
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Tazobactam Approved Phase 3 89786-04-9 123630
Piperacillin Approved Phase 3 66258-76-2 43672
Vancomycin Approved Phase 3 1404-90-6 441141 14969
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
Iodine Approved, Investigational Phase 3 7553-56-2 807
Morphine Approved, Investigational Phase 3 57-27-2 5288826
Ribavirin Approved Phase 3 36791-04-5 37542
Palivizumab Approved, Investigational Phase 3 188039-54-5
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
Captopril Approved Phase 3 62571-86-2 44093
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
Mercaptopurine Approved Phase 3 50-44-2 667490
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
leucovorin Approved Phase 3 58-05-9 143 6006
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
Polyestradiol phosphate Approved Phase 3 28014-46-2
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
50 Pancreatic Polypeptide Investigational Phase 3 59763-91-6

Interventional clinical trials:

(show top 50) (show all 533)
# Name Status NCT ID Phase Drugs
1 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 A Randomised Study of High Dose Chemotherapy/Radiotherapy and Autologous Bone Marrow Transplantation in Patients With High Grade Malignant Non-Hodgkin's Lymphoma (Kiel Classification) According to Prognostic Groups Unknown status NCT00003815 Phase 3 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate
3 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
4 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
5 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
6 Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
7 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
8 A Randomized Trial to Evaluate Early High Dose Therapy and Autologous Bone Marrow Transplantation as Part of Planned Initial Therapy for Poor Risk Intermediate/High Grade NHL Unknown status NCT00003578 Phase 3 CHOP regimen;carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisone;vincristine sulfate
9 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
10 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
11 A RANDOMIZED PROSPECTIVE TRIAL OF CHOP VERSUS MCOP IN ELDERLY PATIENTS WITH INTERMEDIATE AND HIGH GRADE NON-HODGKIN'S LYMPHOMA (AGED 65 YEARS AND OVER) Completed NCT00002576 Phase 3 cyclophosphamide;doxorubicin hydrochloride;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
12 RANDOMIZED COMPARISON OF ALTERNATING TRIPLE THERAPY ("ATT") VERUS CHOP IN PATIENTS WITH INTERMEDIATE GRADE LYMPHOMAS AND IMMUNOBLASTIC LYMPHOMAS WITH INTERNATIONAL INDEX 2-5 Completed NCT00002565 Phase 3 CHOP regimen;cisplatin;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;idarubicin;ifosfamide;mesna;methylprednisolone;mitoxantrone hydrochloride;prednisone;vincristine sulfate
13 Phase III Trial Comparing CHOP ot PMitCEBO in Good Risk Patients With Histologically Aggresive Non Hodgkin's Lymphoma Completed NCT00005867 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
14 Phase III Trial of CHOP Versus CHOP and Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Older Patients With Diffuse Mixed, Diffuse Large Cell and Immunoblastic Large Cell Histology Non-Hodgkin's Lymphoma Completed NCT00003150 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
15 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
16 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
17 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
18 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
19 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
20 Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study] Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
21 The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial Completed NCT00003341 Phase 3
22 Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL) Completed NCT00003215 Phase 3 CHOP regimen;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;melphalan;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;therapeutic hydrocortisone;vincristine sulfate
23 A Randomized Prospective Study of Early Intensification Versus Alternating Triple Therapy for Patients With Poor Prognosis Lymphoma Completed NCT00002835 Phase 3 Carmustine;Cisplatin (CDDP);Cyclophosphamide;Cytarabine (ARA-C);Etoposide (VP-16);Idarubicin;Ifosfamide;Leucovorin Calcium;Melphalan;Methotrexate;Methylprednisolone;mitoxantrone hydrochloride (DHAD);Vincristine Sulfate
24 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
25 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
26 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
27 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
28 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
29 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
30 SWOG-9704 A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+ B Cell Lymphomas (With Possible Late Autologous Stem Cell Transplant) for Patients With Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate and High Risk International Classification Prognostic Groups Completed NCT00004031 Phase 3 CHOP regimen;carmustine;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
31 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
32 Randomized Study Comparing an Immuno-Chemotherapy With 6 Cycles of the Monoclonal Anti-CD20 Antibody Rituximab in Combination With 6 Cycles of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, Both With or Without Consolidating Radiotherapy or Large Tumour Masses (≥7.5 cm) and/or Extranodal Involvement in Patients With Aggressive CD20 B-Cell Lymphoma Aged 18 to 60 Years With Age-Adjusted IPI=1 (All) or IPI=0 With a Large Tumour Mass (≥7.5 cm) [UNFOLDER 21/14 Study] Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
33 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
34 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
35 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
36 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
37 A Phase III Study of Large Cell Lymphomas in Children and Adolescents: Comparison of APO vs APO + IDMTX/HDARA-C and Continuous vs Bolus Infusion of Doxorubicin Completed NCT00002618 Phase 3 cytarabine;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;vincristine sulfate
38 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
39 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
40 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
41 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
42 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
43 Randomized Trial of Autologous GVHD for Refractory Lymphoma Completed NCT00003414 Phase 3 busulfan;cyclophosphamide;cyclosporine
44 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
45 Glutamic Acid to Decrease Vincristine Toxicity in Children With Cancer Completed NCT00369564 Phase 3 glutamic acid
46 Randomized Trial of CHOP Chemotherapy With or Without Rituximab (Chimeric Anti-CD20 Antibody) for HIV-Associated Non-Hodgkin's Lymphoma Completed NCT00003595 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
47 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
48 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
49 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
50 Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMT CTN #0401) Completed NCT00329030 Phase 3 Autologous transplantation using rituxan/BEAM;Autologous transplantation using Bexxar/BEAM

Search NIH Clinical Center for Plasmablastic Lymphoma

Genetic Tests for Plasmablastic Lymphoma

Anatomical Context for Plasmablastic Lymphoma

MalaCards organs/tissues related to Plasmablastic Lymphoma:

B Cells, Bone, Bone Marrow, T Cells, Skin, Lymph Node, Liver

Publications for Plasmablastic Lymphoma

Articles related to Plasmablastic Lymphoma:

(show top 50) (show all 522)
# Title Authors PMID Year
Blastic variant of plasma cell myeloma mimicking squamous cell carcinoma of the uterine cervix in a super-morbidly obese female. 38
31249854 2019
Plasmablastic Lymphoma Versus EBV-Positive Myeloma. 38
31388277 2019
Plasmablastic Lymphoma of the Nasal Septum. 38
31318382 2019
High Incidence of MYC Rearrangement in HIV-Positive Plasmablastic Lymphoma. 38
31348551 2019
Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement. 38
31257571 2019
Oral lesion as the primary diagnosis of non-Hodgkin's lymphoma: a 20-year experience from an oral pathology service and review of the literature. 38
31286184 2019
Extra-oral plasmablastic lymphomas in a high HIV endemic area. 38
31361906 2019
Follicular lymphoma suggested to transform into EBV-negative plasmablastic lymphoma. 38
30859398 2019
A Unique Case of Testicular Plasmablastic Lymphoma in a Patient with Human Immunodeficiency Virus. 38
31410322 2019
Therapeutic Potential of Checkpoint Inhibitors in Refractory Plasmablastic Lymphoma. 38
31377210 2019
Breast Implant-associated Plasmablastic Lymphoma: A Case Report and Discussion of the Literature. 38
31383476 2019
Plasmablastic lymphoma presenting as a brachial artery aneurysm associated with haemodialysis arteriovenous access ligation in a renal transplant patient. 38
31244374 2019
Clinicopathologic features, management, and outcomes of plasmablastic lymphoma: A 10-year experience. 38
30734351 2019
Diverse clinical and histopathologic features of cutaneous post-transplant lymphoproliferative disorders: A presentation of two cases. 38
31144292 2019
Fifty Shades of GATA2 Mutation: A Case of Plasmablastic Lymphoma, Nontuberculous Mycobacterial Infection, and Myelodysplastic Syndrome. 38
31279773 2019
Cutaneous localization of plasmablastic multiple myeloma with heterotopic expression of CD3 and CD4: Skin involvement revealing systemic disease. 38
31025408 2019
SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target. 38
29785767 2019
Solitary Primary Central Nervous System Plasmablastic Lymphoma in a Young Immunocompetent Female: Report on an Extremely Rare Entity with Review of Literature. 38
31143278 2019
Highly aggressive plasmablastic neoplasms in patients with rheumatoid arthritis treated with methotrexate. 38
30658314 2019
Primary central nervous system plasmablastic lymphoma in an HIV-positive patient. 38
30872336 2019
[Intestinal intussusception in adults, atypical and potentially dramatic]. 38
30793557 2019
Plasmablastic lymphoma presenting with ileocecal intussusception in an immunocompetent patient. 38
30808128 2019
Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues. 38
30380402 2019
Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. 38
30804486 2019
Epstein-Barr Virus-Positive CD20- and CD45-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge. 38
29968492 2019
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. 38
29527667 2019
Plasmablastic lymphoma of the rectum, a rare cause of lower gastrointestinal bleeding: A case report. 38
30665721 2019
A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma. 38
30906602 2019
Plasmablastic lymphoma of bone marrow: Report of a rare case and immunohistochemistry based approach to the diagnosis. 38
30706870 2019
HIV-associated lymphoma: A 5-year clinicopathologic study from India. 38
30706863 2019
Central nervous system plasmablastic lymphoma evolving from polyclonal plasmacytosis. 38
29984820 2018
Clinicopathological analysis of oral plasmablastic lymphoma: A systematic review. 38
29917262 2018
Plasmablastic lymphoma masquerading solitary plasmacytoma in an immunocompetent patient. 38
30344143 2018
[Clinicopathological Characteristics and Prognosis Analysis of the Patients with Plasmablastic Lymphoma]. 38
30295249 2018
Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. 38
29303024 2018
A case-control study of HIV infection and cancer in the era of antiretroviral therapy in Rwanda. 38
29663358 2018
Non-Hodgkin's lymphoma of the oral cavity and maxillofacial region: a pathologist viewpoint. 38
30058399 2018
Transformation of double-hit follicular lymphoma to plasmablastic lymphoma: a partial role of MYC gene rearrangement. 38
30012920 2018
Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma. 38
29679112 2018
ESMO Consensus Conference on malignant lymphoma: management of 'ultra-high-risk' patients. 38
29924296 2018
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. 38
29984868 2018
Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course? 38
29081245 2018
Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma. 38
29753690 2018
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report. 38
29879938 2018
Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells. 38
29380399 2018
Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study. 38
29862615 2018
The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma. 38
29257907 2018
Dual Threat of Epstein-Barr Virus: an Autopsy Case Report of HIV-Positive Plasmablastic Lymphoma Complicating EBV-Associated Hemophagocytic Lymphohistiocytosis. 38
29687211 2018
Plasmablastic Lymphoma in a Patient With Crohn's Disease After Extensive Immunosuppressive Therapy. 38
28782668 2018
Plasmablastic lymphoma presenting as a ureteral polypoid mass. 38
29692511 2018

Variations for Plasmablastic Lymphoma

Expression for Plasmablastic Lymphoma

Search GEO for disease gene expression data for Plasmablastic Lymphoma.

Pathways for Plasmablastic Lymphoma

Pathways related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
Show member pathways
3 12.22 PTPRC PRDM1 CD38 BCL6
6 11.84 VDR PRDM1 BCL6
8 11.71 MYC CDKN2A BCL6
9 11.69 MYC MUC1 BCL6
10 11.65 MYC MTOR CDKN2A
11 11.52 PTPRC NOTCH1 MS4A1 CD38
12 11.41 PTPRC MS4A1 CD38
Show member pathways
Show member pathways
10.91 MYC CDKN2A
15 10.9 MYC CDKN2A
16 10.77 VDR ABCB1
17 10.75 PTPRC PRDM1 MS4A1 CD38 BCL6
18 10.7 MTOR ABCB1
19 10.69 VDR ABCB1

GO Terms for Plasmablastic Lymphoma

Cellular components related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.36 VDR PRDM1 NOTCH1 MYC MUC1 MTOR

Biological processes related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.83 VDR PRDM1 NOTCH1 MYC BCL6
2 negative regulation of cell proliferation GO:0008285 9.78 VDR NOTCH1 CDKN2A BCL6
3 regulation of cell proliferation GO:0042127 9.69 PRDM1 NOTCH1 BCL6
4 negative regulation of transcription, DNA-templated GO:0045892 9.65 VDR NOTCH1 CDKN2A CD38 BCL6
5 response to gamma radiation GO:0010332 9.52 PTPRC MYC
6 negative regulation of cell-matrix adhesion GO:0001953 9.49 CDKN2A BCL6
7 positive regulation of glial cell proliferation GO:0060252 9.46 MYC MTOR
8 positive regulation of keratinocyte differentiation GO:0045618 9.4 VDR NOTCH1
9 energy reserve metabolic process GO:0006112 9.37 MYC MTOR
10 positive regulation of B cell proliferation GO:0030890 9.33 PTPRC CD38 BCL6
11 somatic stem cell division GO:0048103 9.32 NOTCH1 CDKN2A
12 cell cycle arrest GO:0007050 9.26 NOTCH1 MYC MTOR CDKN2A
13 positive regulation of gene expression GO:0010628 9.1 VDR PRDM1 NOTCH1 MYC MTOR CDKN2A

Molecular functions related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.62 PRDM1 NOTCH1 MYC MUC1
2 DNA-binding transcription factor activity GO:0003700 9.55 VDR PRDM1 NOTCH1 MYC BCL6
3 sequence-specific DNA binding GO:0043565 9.35 VDR PRDM1 NOTCH1 MYC BCL6
4 chromatin DNA binding GO:0031490 8.8 PRDM1 NOTCH1 BCL6
5 protein binding GO:0005515 10.03 VDR PTPRC PRDM1 NOTCH1 MYC MUC1

Sources for Plasmablastic Lymphoma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....